Best Stock Is Waitting You To Invest

Ever heard the story about someone who became mega rich overnight by buying a pharma best stock…just before a new drug was approved?

Do you ever sit around and think, "I read a ton of information… I do a lot of stock research…so why haven't I hit my own pharma home run yet?"

Sometimes that just doesn't seem fair, does it?

You and I know that those people who got rich off of a pharma stock are not smarter than you. They've just been lucky enough to have access to "inside" information…

Well, today you have your own chance to get the "inside" information you need to win the FDA game…

You see, our friends over at Stansberry & Associates Investment Research just came across a penny stock pharma company that could land you some serious cash when the FDA announces results on their latest drug.

As soon as I read this report, I couldn't wait to share it with you.

If growing rich overnight on the next pharma breakthrough sounds appealing, just continue reading for all of the details…

We've waited 2 years for this day.

On March 30th, there'll be an announcement of FDA results for a new drug that could create the single biggest return of any investment we've ever found, in 10 years.

"All eyes are on the data," says Business Week. "It could be a multi-billion dollar drug, and so far, all the numbers have been positive." BioWorld writes: "It could be the largest pharmaceutical market ever."

When you see (below) what the drug treats... I think you'll see why S&A has now spent over $200,000 since 2006, uncovering the full details.

"It's the perfect storm," writes drug expert Jack Windin. "A totally new chemical entity with virtually no competition."

So far � the drug has successfully cleared both Phase 1 and 2 FDA clinical trials... and is just weeks from the announcement of Phase 3 results... the last trial before it could launch on a scale potentially unseen since the release of penicillin.

As Forbes reports: People across America are already writing letters to the small company who owns the patent... asking: "How can I get your drug?"

But the big question, of course, is: "Will the drug be approved by the FDA?"

By March 30 � we'll hear the official announcement of test results. It's a decision we've been following daily since trials first began more than 2 years ago.

And while most people have no idea what will happen... we've been able to access early results directly from the company, and they're even better than we hoped.

In short: as of Dec. 15, 2008, early clinical results suggest the drug is safe... has a near-perfect success rate... has a 500% efficiency... and finally, get this: will target 45% of the U.S. population � almost 1 out of 2 Americans.

As one FDA expert puts it: "If results on March 30th turn out even half as good as we expect... this could be the best-selling drug in the history of medicine."

Best of all: All the rights to the drug belong to a single company, a penny stock. At today's prices... a 4-point jump alone would double your money.

In other words: if the results are positive for this new drug on March 30th as we expect... a single stake in this company could make you a fortune, overnight. We estimate as much as $195,600... but only if you get in right now (you'll see why below).

Again, we've waited 2 years for this day. It's the kind of situation we built our firm on back in 1999... investments that can literally change your life.

Let me give you the full story...

Forbes: "The magic pill"

Years from now � and perhaps for the rest of their lives � a small group of people will remember exactly what they were doing on March 30, 2009.

You see, by that morning, there will be an announcement that's unlike just about any other FDA-related release. It's the single announcement that allows regular investors like you and me the rare chance to make a small fortune...

• When Celgene (CELG) heard a similar announcement in 1998, for example, the best stock to buy returned 1,002%... turning every $5,000 into $50,100 profit. (We're expecting an even bigger return this March.)
  
  
• The same thing happened in 1991 to Amgen (AMGN) � which immediately doubled... and went on to gain an unbelievable 1,700%.

In short � by March 30th... we're expecting an announcement of something more than just new drug approval...

Quite simply, we expect approval for a new drug unlike anything to ever go public in the 81-year history of modern biotech. It's a drug that simply hasn't existed, in any useable form... until the company I'm telling you about invented it.

And yet it offers the one cure that almost everybody wishes for � at some point in life. (Don't worry, I'm not talking about something farfetched, like a cancer cure... or a fountain of youth.)

In fact, chances are you know someone who could benefit from the drug, and will even prescribe to it... after test results come out by March 30th.

The drug could help so many people a neuroscience writer in Dallas went as far as to say recently, "The FDA should lower requirements and speed up approval."

It's been described by even conservative health writers with words like: "runaway bestseller"... "blockbuster potential"... and "sell like gangbusters." Forbes wrote of the "magic pill," and went on to say:

"If approved, it could be a billion-dollar drug."

To put that in perspective: If the penny stock company that owns this drug makes even half that amount in revenue... the share price could rise by almost 1,000%.

Now you can see why all of us here at S&A are waiting for March 30th.

You see, only less than 1% of new drugs ever make it past the laboratory door... and through the FDA... for release to the American public.

But this situation is even rarer.

Simply put: not only do early test results suggest the FDA will grant its approval... but in addition � the drug would create an entirely new market, the likes of which no biotech firm... anywhere... has ever successfully tapped.

Let me explain...

Last untapped drug market

Last month, on January 11th, Brian Jennings of NBC Nightly News ran a top-of-the-hour story on a growing epidemic sweeping America...

According to the Centers for Disease Control and Prevention, it's already begun to affect two-thirds of the U.S. population � whether folks realize it or not.

Even more startling is the World Health Organization report: 1 out of 6 people worldwide are now affected by the medical problem being successfully treated by the drug I'm telling you about. That's ONE BILLION PEOPLE.

The problem has grown into such a major health concern MarketWatch reports that its treatment is now among the Top 10 Priorities of the U.S. Government.

And yet... there's no single drug available to treat it.

Big Pharma is pouring tens of millions into the effort. Many speculate a drug that successfully treats this problem (which I'll reveal below) would be, "the last of the traditional blockbusters... drugs that weigh in over $1 billion annually."

One drug expert calls the market the "biggest untapped goldmine in the industry" and speculates that it would be worth $10 billion per year.

That's why shares of the little drug developer I've been telling you about could go through the roof on March 30th, on the announcement of Phase 3 test results.

The reason: They have the #1 leading drug in development right now to treat this problem... and they're the only one of its kind right now to have completed both Phase 1 and 2 trials... and potentially tap the largest pharmaceutical market ever.

But the most important reason why this penny stock could jump so quickly come March 30th boils down to just one thing:

The drug works.

In a move quite rare in drug trials... many of the actual patients who are currently enrolled in tests are breaking doctors' orders to speak out in public.

"It's working great," says one patient � a 35-year-old woman. "I can't wait for it to come out. I feel it has been a great thing for me," says a 64-year-old man.

In December 2008, our top medical analyst uncovered early test results directly from the company.

And look at this: Last July � one of the biggest critics of the drug, Sandy Karle, an expert in the field (which I'll reveal below), wrote: "Forget it!" warning that it may not be possible to ever successfully treat this problem with drugs.But days later... after learning more, she publicly said:

"I am tempted to buy the stock. [This tiny company] will make a mint, and so will its investors. If you're looking to make money... it's a good choice."

So what does this drug cure, exactly? And why do experts think it could tap one of the last billion-dollar-drug markets in pharmaceutics?

Near 100% success rate

In short � the drug treats obesity.

With just a single pill... it lowers the patient's weight by at least 5% (the golden number in weight loss). If a patient can lose 5% of fat � academic studies have shown that this significantly lowers blood pressure... risk of heart disease, and other harmful effects like diabetes... arthritis... and stroke.

Even more amazing � unlike almost every other weight-loss alternative, the drug works without a single ounce of effort from the patient.

In other words: It requires no exercise... no special diet... and no risky operations in the hospital. You simply swallow the pill on a full or an empty stomach.

As one patient in the Phase 3 trial recently said, "I've lost 21 pounds (10% of my body weight) in 10 weeks. I couldn't be happier. I'm excited, because I wouldn't mind being able to wear a single digit size by next summer!"

"I have lost about 90 pounds," another patient said last month.

And a third Phase 3 patient recently said, "I lost 20 lbs (I weighed 160), my blood pressure went down, my cholesterol went down, all my levels are great now."

As I'll explain � the drug works by targeting a little-known part of the brain. (The British scientist who helped invent it detailed the entire process to us in his office.)

Specifically � it targets the brain area that controls the patient's appetite. When a patient takes the drug twice a day, it suppresses his appetite and he finds himself naturally eating less and less...

That's why folks struggling with their weight are so excited. It doesn't require any difficult program or diet � like the Jenny Craig work-out routines... or the untasty meals of NutriSystem or WeightWatchers.

When you prescribe to this new drug, you eat what you want, as often as you like. It's that simple. For folks who want to lose weight without sweating or sacrificing, it's about as good as it gets.

And as I said before � there's no other single drug on the market that offers it any real competition whatsoever. As Forbes recently wrote � the only two alternatives on the drug market deliver "mediocre results."

This drug, on the other hand, uses an entirely new molecular compound that has been patented by the company behind it... a compound so unique that practicing physicians nationwide are already taking notice...

At a recent meeting of the American Diabetes Association, for example, Dr. Steve Sarton, M.D., of the Biomedical Research Center devoted his talk to it, saying:

"The drug demonstrated excellent weight loss in this study � coupled with excellent tolerability and a positive impact on associated physical measures in obese patients."

In other words: The drug works.

But before I show you how it works... (and why we believe that even a small stake could make you as much as $195,600, overnight)... let me make something clear:

May not be right for you

Unless you're willing to act on this situation immediately � long before March 30th, when FDA results are announced � this investment may not be right for you...

You see � the big money in new drug development comes weeks... often months... in advance of FDA approval. And unless you act quickly, you miss out...

• Take Oncogenex (OGXI), for example. A lung cancer drug they developed, OGX-011, hasn't even entered Phase 3 trials... and yet the stock is already up 1,728%.
  
  
• Or look at Medivation (MDVN). Their new drug for Alzheimer's, Dimebon, is still in Phase 2 trials. But the best stock for 2010 is up 1,756%.

The point is � most people have never even heard of the little company who made the drug I'm telling you about... which is one reason it's still a penny stock.

But it's only a matter of weeks � even days � before this changes...

An almost identical situation recently played out with Auxilium (AUXL)... an East Coast drugmaker. Nobody had ever heard of this company when it began Phase 2 trials for a new testosterone drug...

But on October 26, 2005 � before results were even public... the executives held a press conference at The Palace Hotel in New York, to talk about it.

Just 5 DAYS LATER... on Oct. 31... the stock began a 973% run.

And unless you'd gotten in before the press found out... you'd have totally missed out on this situation. By waiting, you'd have missed a near-10 BAGGER.

Well � this opportunity is even bigger. And the reality is: The top stocks to buy could start its run any day now. The company issued 3 press releases in December alone. We're expecting an even bigger press release about the drug literally at any minute.

But whether you follow our advice... or wait until the last second, there's only one thing you need to know about this drug to make a fortune...

Secret of top 100 drugs

You see � the top 100 bestselling drugs in history all have one thing in common... as do 50% of all successfully launched drugs of the past 30 years...

In short, they're all compounds that target proteins in the human body known as the "G-protein-coupled receptors" (or "G-proteins" for short). Most people have never heard of it, but this secret little protein has produced over $30 billion in sales on the drug market.

Well... the drug I'm telling you about also targets "G proteins."

But unlike 99% of the market, it does something no other biotech firm, anywhere, in the history of pharmaceutics, has ever safely accomplished...

Quite simply: It targets "G proteins" in the brain, activating a single very tiny portion that controls appetite... the feeling of being "full" after eating.

This part of the brain is known as the "hypothalamus," and is filled with the same chemical that controls sex... and sleep. But what makes the drug so unique is that it can isolate and activate the "appetite" part alone... with 100-FOLD selectivity over the other 2 parts... the only drug to have ever done this.

Targeting G-proteins � the drug literally enters your brain... and sends out a chemical message saying, in effect: "You're full. There's no need to eat any more."

As I said before... the top 100 bestselling drugs in history
have used the G-protein secret in a similar way � but never, ever, to treat obesity. What this means for you, as an investor, is just one thing. Take a look...

Here are 4 examples of other "G-protein" drugs... and how much they made after receiving FDA approval and launching worldwide...

The best part: If the penny stock behind this new obesity drug were to make only a fraction of those numbers � say $250 million � the stock could triple.

If it made $500 million in sales... it could rise 978%. And if it made one billion in sales... the price could rise 1,956%. That turns every $10,000 stake into an unbelievable $195,600 profit.

Now you can see why BusinessWeek says, "All eyes are on the data" and why S&A has spent over $200,000 since 2006 uncovering the full details...

And that's not all...

A 229%, 1-day perk

There's an extra perk to this opportunity, which could make you another 229%... in the space of just 8 hours or less...

Now bear in mind: The real money you should expect to make from this drug will come as a result of March 30 � when the Phase 3 test results are announced.

But there's a good chance that before this happens... this tiny company will accept a lucrative licensing offer from a larger biotech firm. In fact � when we spoke to the firm's CEO at their headquarters, he said he's already on the lookout for a deal...

• The windfall could be enormous. Take SGX Pharma (SGXP), for example... When they accepted a licensing offer from Eli Lilly on July 8, 2008, they saw a 125% 1-day jump in share price.
  
  Kosan Biosciences (KOSN) made a 229% 1-day jump after a licensing offer from Bristol-Myers (BMY) on May 28, 2008.
  
  
• And Barrier Therapeutics saw a 128% 1-day jump on June 24 of last year after a licensing offer from privately-held Stiefel Labs.

Again: this is only an added perk. We expect the real gains in share price to arrive as a result of March 30th � the day we've been awaiting for 2 years...

But given the company's history, there's a high probability a licensing deal could happen any day now... as early as next week... or even tomorrow morning.

You see � this tiny drugmaker has already used its "G-protein" approach to make two other brand-new drugs, which have both been licensed, by the biotech giants Johnson & Johnson... and Merck (multibillion-dollar heavyweights).

**The Merck deal is for the company's heart drug... which began a Phase 2 trial recently that triggered a $4 million payment to the firm, with another $32 million in potential royalties.

**The Johnson & Johnson deal is for the company's diabetes drug... worth $295 million in future royalties.

In short... there's a good chance this company will strike another deal with a giant firm (with a greater marketing budget), to license the drug I'm telling you about... especially given that the obesity market is being called "an untapped goldmine."

And if that happens, you could see an extra 229% 1-day jump in share price, more than doubling your money if you own shares before the announcement...

Coffee with the CEO

But before I give you the specifics on how to play this stock, you should know that our analysis comes from a single source we've been using since 2002...

It's easily S&A's #1 biotech secret � and has already pointed to some of the fastest and biggest gains we've found in this sector since our firm first began...

Like Crucell (CRXL), for example, a vaccine maker that shot up 1,145% since we first told readers about it. Or Sirna (RNAI)... which was bought out by Merck after we found it and doubled overnight, a 201% gain.

In short, I'm referring to Rob Fannon.

Unlike most of our analysts... Rob doesn't get his information through traditional means. He doesn't sit behind a laptop all day, reading financial reports... or trying to cold-call company executives for a hot tip...

Quite simply � Rob uses his personal connections in the academic and the private sectors of medicine, obtaining data most people never see until it's too late...

For example, Rob was the first to tell us about Esperion... a firm that developed a radical new way to treat heart disease. By chance, he worked down the hall in Los Angeles' Cedars-Sinai Hospital and Research Center from one of their top clinical researchers � Dr. P.K. Shah, a man who's been profiled by USA Today.

By getting to know him, Rob learned that Esperion's Phase II test results showed their drug could successfully remove arterial plaque � reversing heart disease.

Rob immediately gave us the full details... and 3 WEEKS LATER, Rob's readers saw 55% gains OVERNIGHT, when the company was sold to Pfizer.

For the drug I've been telling you about � Rob has been using his connections for the past 2 years, ever since he first learned about it in 2006 from the CEO.

Since then... we've allowed Rob a budget of almost a quarter million dollars to learn more. That may sound like a lot of money... but it's been more than worth it. Take a look:

Rob flew out to the company headquarters... toured their private facility... and met over coffee with the CEO, to find out exactly when the drug will be ready. He then met the drug's British inventor, joining him in his office... a room lined with academic tomes and medical journals.

Later Rob called a Ph.D. gastroendocrinology expert at Johns Hopkins University... and then held a conference call with both his Hopkins Ph.D. contact and the company's CEO, to discuss even further.

In short, Rob probably knows more about this new drug than any other analyst in America. He's really the only person you should follow to profit from it...

You see, when it comes to making money in biotech... you have to understand the science... you have to understand the business. And you have to develop contacts. All this costs tens of thousands of dollars and many years to accomplish...

That's why Rob's full report on this drug � March 30: Biotech's Last Great Blockbuster � (details below) will show you exactly how to get in right away... for the biggest return in the shortest amount of time.

But is this investment right for you?

Well... whether you put your money in this penny stock or not, all I can say is that when it comes to finding little biotech firms that can make people a fortune... I've never met anyone with better inside access than Rob Fannon...

• Long before we ever hired Rob, for example, he analyzed Intuitive Surgical (ISRG) for us, a surgical device maker. It rose 133%.
  
  
• Same thing with Elan (ELN), a drugmaker for immune disorders. Rob was among our consultants... and the hot stocks for 2010 skyrocketed over 400%.

But there's another reason why Rob's research can make you rich...

Early stage windfalls

Passing him on the street, you'd probably never even notice Rob Fannon...

A quiet man, he spends his days in a small office peering through his pair of dark-framed glasses at medical journals (The New England Journal of Medicine), and pausing to look out the window at the Baltimore skyline.

But throughout his career, Rob has uncovered a proven way to make the quickest, biggest gains on no-name biotech stocks, a strategy for uncovering the best early- stage windfalls in the business (like the overnight double on RNAI).

In a nutshell: he's a Phase 1 trial expert.

A Phase 1 trial, as you probably know, is the first step in FDA clinical trials before a company can receive approval for a new drug or medical treatment.

The most profitable "Phase 1" developments are those made by small, early-stage companies with BIG IDEAS that can change the face of medicine... with potential to grow 1,000% or more... like the one I've been telling you about in this letter.

I've been in the financial business for almost a decade, and even now � after everything I've seen � nothing compares to the feeling of watching a tiny stock take off, turning a small stake into a bigger sum of cash than you've ever made on a single investment.

It's how I felt when we recommended JDS Uniphase, for example � which gained 592%... Texas Instruments (301% gains)... Cree (271% gains)... and Seabridge (700%+)... among many others.

These are the situations Rob specializes in... Put simply: To really make money with drugmakers... you absolutely MUST know the scientists... researchers... doctors... FDA officials and CEOs who understand � long before Wall Street � where the next "big thing" is coming from.

Experts in every industry always know more than outsiders, but when it comes to FDA test results like those we're anticipating on March 30th... where approval can make or break a company... "on the ground" perspective is critical.

Frankly: these are the kinds of investment opportunities that can literally change your life... where an investment of $10,000 can quickly turn into enough to buy a beach house... or pay for several kids' college education... or allow you to just quit your job � forever � and retire on the proceeds.

It happens a lot more than most people think � you just have to know about the RIGHT company at the RIGHT time... with help from the experts directly involved.

Now you can see why Rob has gone through a $200,000 budget to research the company I'm telling you about...

Again: this penny stock has already put the drug through its PHASE 3 trial, which will have its results announced by March 30th.

And it gets even better...

Not only has Rob prepared a detailed Research Report giving you the full story of this company... and how to get in for the biggest possible gain... but:

Rob has also found a secret way to eliminate much of the risk in the best stock for 2010, while giving you an even FASTER way to see a triple-digit upside.

Let me explain...

Shortcut: 400% upside

There are 2 ways to play this opportunity.

The first is by simply buying shares of the penny stock, which Rob outlines in his full report.

But there's a second play that you can use to get into the stock... and as a result � reduce your risk to almost nothing while shortcutting to 400% in possible returns. We've done this many times before at S&A Research...

• For example: last July we did this with healthcare firm Palomar Medical (PMTI)... and saw 490% gains on just a tiny move in the stock.
  
  
• Or consider March 2007. The FDA announced test results for a new drug by Dendreon (DNDN)... and S&A readers saw a 314% jump in the stock. But by following our 2nd play � some made even more...
  
  Joe Samuels from Woodland, Calif. saw a 1,017% return in less than 48 hours... enough to turn every $5,000 stake into $50,850. And John Bailey saw a 771% return from the FDA announcement.

In short � Rob is also recommending an options play.

You see, with options, you can make 10 TIMES the return of a stock... often even more. All it takes is just a tiny move in share price to make you a killing.

For example, in early December we published an options play for Silver Wheaton (SLW), a silver miner. The stock barely moved, inching up 3 points... But readers saw a 250% gain � in just 14 DAYS.

That's the great thing about options: Not only can you make more money, but the return comes FAST... in many cases, on the exact same day you get in:

That's why in Rob's full report about this situation, he'll be including details on a secret options play � a way to ensure that even the tiniest move in the stock could shoot your return many times higher, immediately, to at least 400%.

But I know what you're thinking: "Options are risky..."

Well, the truth is � by using options you can actually REDUCE your risk. It's simply a matter of poring through dozens of potential plays, looking for the perfect option. And in biotech, that requires days of analysis by only a veteran trader.

Fortunately for Rob... he's got a secret weapon in the options business.

Meet Dr. George Huang � a Ph.D. biochemistry expert who specializes in options biotech plays, with a focus on companies on the verge of major buyouts:

• When Indevus Pharm. (IDEV) got bought out by Endo (ENDO) in early January... Dr. Huang's options play saw a 186% 1-day gain.
  
  
• Dr. Huang's play for Neurocrine Biosciences (NBIX) saw an astonishing 100% gain in just 14 days. His play on ImClone... 100% in 30 days. And Alpharma.: 100% in 58 days.

Quite simply: With additional analysis from Dr. Huang, Rob has pinpointed what we believe is the single most effective and safest options play for this situation.

In Rob's new report � March 30: Biotech's Last Great Blockbuster � he'll explain exactly how to execute the play... for the biggest gain in the shortest time span.

If you'd like to get a copy... well, I have some bad news.

As I warned you earlier, this investment opportunity won't be right for you unless you're willing to execute Rob's recommendation immediately.

But there's another reason why this situation may not be right for you... especially in today's markets and economy. So I urge you to read on carefully.

Be aware of 3 things:

To put it gently: Unless you can afford it... Rob's research is probably not the best thing for you right now. And in fact � it probably never will be...

You see � unless you're one of the more experienced readers: You simply don't have the resources to 1) pay full price for this work (see below)... and 2) take a large enough stake in the play for a chance at making real money.

But more importantly...

3) Unless you're comfortable making very speculative plays in top stocks, which most people have never heard of, or unless you just want to watch and learn � you'll be wasting your time.

Said differently: The investment opportunities Rob uncovers aren't for ordinary investors: Folks who wait around for dividends and rely on 401(k)s. It isn't meant for amateurs trying to get a hot tip to pad their Social Security income...

If that sounds like you, please stop reading now.

In short, we only publish Rob's research for a very small audience: folks who have the resources to afford it... cash in on it... and might want to stomach the often bumpy ride of biotech � which most people try to avoid.

And that's why we're limiting access to Rob's new Research Report (March 30) to our most expensive and sophisticated advisory service: Phase 1 Investor.

To my knowledge � there's no other investment research service in the world that compares to Phase 1 Investor. It costs more to produce than any other advisory at S&A Research... not just in terms of
money, but in sheer time alone.

Tracking down tiny companies with early-stage breakthroughs takes months and sometimes years
of research. (As I said before: we've waited 2 years for test results on the drug I've been telling you about.)

Tens of thousands of dollars go into each new recommendation, on travel (air and hotels)... consultant fees... lab tests (on occasion)... and conference meetings.

To keep up with modern biotech, every month, Rob logs hundreds of air miles, to attend meetings for The American Society of Hematology... The American Society of Clinical Oncology... The Drug Information Association... and many other major meetings of the world's top medical specialists.

In other words: Phase 1 Investor is where we publish our most rigorous research.

As a matter of fact: That's one reason we hired Rob. Most analysts hate doing the legwork of research, but there's nothing Rob loves more than flying around the country to meet with executives and key personnel behind Phase 1 trials. (It's not surprising, given his background...)

You see � Rob studied physiology and biochemistry as an undergraduate, and has worked as a scientist in both the academic setting and the private sector.

He got his first big break from the Government's top medical headquarters... The National Institutes of Health (NIH)... where the country's best scientists evaluate new drugs and medical breakthroughs, and award billions in grants.

 

In particular, he did NIH genetics work for a Maryland-based biotech company... which he helped expand, by setting up a new division in Hyderabad, India.

At Johns Hopkins University, the country's top medical school... he got a Masters degree in Public Health, an MBA, and made several key contacts.

He also worked at Cedars Sinai Medical Center, in the prestigious Comprehensive Prostate Cancer Research Program, where he made other contacts (such as Dr. P. K. Shah, who tipped him off to Esperion � which gained 203%.)

Bottom-line: Rob is uniquely qualified in this business.

In fact, when Rob finished school... at first we didn't think he would come to work for us... especially after what he said during his interview:

 

"I don't want to write any advertisements," he told us right away. "I don't like any hype."

You see: Rob has never been comfortable with financial advertising � which of course portrays every single investment idea as the Holy Grail of Biotech... the cure of cancer... and so on.

In fact, for many months in the beginning... he didn't allow us to advertise Phase 1 Investor at all. Unless you knew about it, there was no real way to get in.

But that's what I love most about Rob: He's conservative. He's quiet. He's safe. I'll give you a quick example... so you can see how important this is in biotech.

A while back... Rob found a tiny biotech company called Renovis (RNVS) that had just developed a new drug for stroke victims.

From a medical standpoint, Rob found the drug � and the company behind it � compelling... so he immediately paid a visit to his friend and colleague, the head of Johns Hopkins University Stroke Research.

Right away � his Hopkins contact said: "No way. You're flipping a coin on this."

Rob scrapped the idea. 3 months later, Renovis TANKED 75% when the Phase III trial failed. Rob avoided this bomb as a result of good, hard diligence.

Bottom-line: When Rob makes a recommendation... you can be sure he's studied it from every angle, to make absolutely sure that you're going to make money.

Walking past his office recently, I saw him hunched over his computer, typing up his new report (March 30)... long after most of our employees had gone home for the day. I knew he'd be there for hours.

But that's exactly what you want when it comes to investing in new drugs: a smart analyst who lives for these situations, interviewing the key insiders who know.

The only question is: Assuming you can afford Rob's research (see below for what we're asking), is this new obesity drug truly the right investment for you?

CEO will brief you

I recommend you decide for yourself after learning the full details from this tiny company's CEO... who will brief you on how it works.

You see, as part of his research � Rob held a conference call with Phase 1 readers and invited the CEO, along with a weight-loss expert at Johns Hopkins... and the full transcript of the call is available online, for all new Phase 1 members.

When you join Phase 1 Investor... you'll receive instant access to the transcript along with Rob's full new report: March 30: Biotech's Last Great Blockbuster.

This isn't a one-time thing, either. Every month, Rob puts together an extremely detailed Research Report on a new Phase 1 opportunity. When appropriate, he'll then host a special Conference Call or Web conference to discuss the situation in full.

Joining Rob on these conferences will be industry insiders, company executives and independent researchers he meets while investigating each new opportunity.

(Of course, you'll be invited to join as well, so you can hear and learn about these new developments and great opportunities firsthand. If you can't make it... don't worry. Rob will always post the conference for you, online.)

**In fact, on February 11th, Rob will be hosting a new conference to discuss this opportunity... featuring biochemical options expert Dr. George Huang, along with Rob's contact at Johns Hopkins University, a professor of medicine who has been studying obesity for almost 20 years... has published 19 science articles about it... and has worked with the Government's NIH.

The conference will be online. Simply log on... and listen. You'll be able to submit any questions you might have � and hear the panel's response.

The only catch: You must reserve your spot immediately. (You can get started by following the link below.)

By reading Rob's full report... and listening to the experts firsthand... you'll know for sure whether or not the investment is right for you.

As you can see � we do everything we can to make sure the recommendations in Phase 1 Investor are among the best-performing research we publish.

As a matter of fact � several CEOs of the companies Rob has recommended have told him his research is the most informed of any analyst they've seen.

And that's why Phase 1 Investor is our most expensive research service.

That said, I believe Phase 1 Investor is actually also the best bargain of anything we publish � considering the amount of time... money... and effort that goes into each new recommendation.

The cost for one full year of Phase 1 Investor is $5,000.

If that sounds like too much money, I can tell you right now: Rob's report won't be right for you. I suggest you look into one of our other research advisories, such as 12% Letter or True Wealth... for folks who are just starting out.

But there is some good news. For reasons I'll explain shortly � for a limited time only, you can get Phase 1 Investor for almost 50% off the standard price.

Quite simply, you can become a member for just $2,600.

Believe me � we don't do this often. Once the offer expires, the price will go right back to $5,000... and will probably stay there for quite some time.

But we're making you this offer because the truth is... we believe the coming year is going to trigger an absolutely incredible biotech bull market. In particular, Rob thinks we'll see a tidal wave of mergers and acquisitions... such as the one we just saw in early January � when Indevus got bought out by Endo. (Rob's readers saw a 1-day gain of as much as 186%. And that's just the beginning...)

 

You see � in the past four biotech bull markets, you could have booked 3 triple-digit gains and one quadruple-digit return... simply by buying the biotech index.

Imagine, on the other hand, banking several-hundred-percent gains on one small stock after another... like the
one Rob shares in his new report: March 30.

As I said earlier, that's why we publish Phase 1 Investor: to focus on the kinds of opportunities we simply can't recommend to a mainstream audience.

If this sounds like something you're interested in, here's what I recommend:

Sign up right now for a trial subscription to Rob Fannon's Phase 1 Investor. You'll have immediate access to Rob's full new report outlining the opportunity I've been telling you about: March 30: Biotech's Last Great Blockbuster.

Even better: You'll have access to Rob's full archive of Research Reports � where you'll learn about 17 more Phase 1 opportunities he still considers a strong buy.

And you'll also receive full details on how to attend the Web conference Rob will be hosting on February 11th, with his panel of biotech and obesity experts.

Then, take the next 3 months to decide if Phase 1 Investor is right for you.

During that time � you'll receive Rob's monthly reports... and be invited to join any special conference-call meetings.

And remember...

As I've said throughout this letter: We're all waiting for March 30, when the FDA results will be announced for a new drug that could soon become "the bestselling drug in the history of medicine," as one experts puts it... and successfully tap "the largest pharmaceutical market ever" (BioWorld). According to Rob, this is one of the most exciting events he's seen in his career. If you're even considering a stake in this company... I urge you: get your hands on Rob's report, immediately.

If you decide Phase 1 isn't for you, simply cancel your subscription before your 3-month trial period is up. You'll get a full refund � 100% � no questions asked.

Remember � your chance to save ALMOST 50% on a full year of Phase 1 Investor will end shortly. After that... this offer expires.

P.P.S. As I mentioned earlier, we believe the announcement on March 30 could create the single biggest gain of any investment we've ever found... in 10 years in the business. But I'm sure you have a few questions about this situation, and I imagine you have a few doubts I haven't covered here.

That's why we've prepared a special "Frequently Asked Questions" section of this letter... which you'll find below, telling you exactly what we know... how we know it... what to expect... and why the biggest potential return could come any day now.

Frequently asked questions:

Q: How can I be sure results will come out on March 30th?

A: Rob Fannon has received a 141-page official document about the drug directly from the company headquarters. On page 12 � it says explicitly that at the end of March, results will be announced.

Q: What if the drug doesn't receive approval?

"I have lost about 90 lbs., can actually exercise, and I can look in the mirror without flinching. Of particular note was the fact that I cannot stand to eat chocolate or fried foods. They both make me nauseated. Quite a change from the dark chocolate gobbling junkie I was prior to the program."

- 45-year-old man in drug trial

"I'm just completing my first week in the study. But as a diabetic, I'm thrilled to say my blood sugar's nearly down to normal from sky high a week ago. I definitely find my appetite's greatly reduced and I have to structure my eating to ensure I don't forget meals."

- 37-year-old woman in drug trial

A: We already know the drug works. We have quotes from patients (see right)... and we have early results from the Phase 3 trial, showing that it beats the placebo (no drug) by 500%... and has successfully treated
almost every single one of those on drug among the 3,000 patients currently enrolled in the clinical trials.

And don't forget: Unlike most new drugs, this one has already cleared the Phase 1 and the Phase 2 trials. In other words: all that's left is the red tape of filing it with the FDA. That's why most new drugs (like the examples I gave earlier) usually see their biggest returns long before the FDA gives official approval.

Having said that � yes, there is always the possibility of this drug not receiving approval. But this is the type of speculation that's definitely worth taking in the investment world... where the odds are extremely high in our favor... along with the very real potential to risk a small amount of capital � and see gains of 400% or more. Of course � you should not get involved if you cannot accept that risk. And even if you can, we recommend you invest only a tiny fraction of your overall portfolio.

Q: What if the results aren't as good as you hope?

A: We believe it won't matter. As you know, the markets rise and fall on emotion more than anything else. Even if results aren't totally perfect � it could attract so much heated attention the drug will appear in newspapers... magazines... and on news shows.

And as I pointed out earlier... once the press catches on to a situation like this, it's all over. The best stock to buy has usually taken off. That's why it's critical to get in before the media hype begins.

Q: What makes you so sure the media will jump all over this event?

A: Well, even as I was writing this letter... we saw 2 separate reports on the NBC Nightly News show about the growing problem of obesity in America. In fact, one story told of how the U.S. Army is taking steps to reduce obesity.

Not a day goes by in this country when there isn't some new study or news report detailing the negative effects of obesity. The bottom-line is: The number of overweight people in America is attracting the notice of medical professionals everywhere, and even the Government.

If this drug goes public � it could be given to so many people, old and young, man and woman, that it would become a household name... create a market worth $10 billion... and turn early investors into millionaires. It's that simple.

Q: What if I decide this investment isn't right for me?

A: No problem. You'll receive 3 full months to give Rob's Phase 1 Investor a no-risk trial subscription. Once you read his report... and look through his archive... if you decide his work isn't right for you, just let us know.

You'll get a total refund � every last cent, no questions asked. And his new report, March 30: Biotech's Last Great Blockbuster, will be yours to keep.

 

 

Pick a Number…Any Number

We didn't abandon the money-supply aggregates. They abandoned us..."

Time was that central banks targeted and fretted about keeping their currency stable against the Dollar.

But as the Dollar-led inflation of 1950-1980 destroyed the value of bonds and savings worldwide ― and then destroyed equities, as well as any sober hope of business and hiring plans ― policy-makers tried to target instead the volume of cash flowing around their domestic economy.

Monetarism in turn fell apart as first the mid-80s "super Dollar" and then globalized deregulation of finance pulled the various "M" aggregates down, up and finally out of the window. "We didn't abandon the aggregates," says one practitioner in Steven Solomon's 1995 book The Confidence Game; "they abandoned us."

Central banks already had a new hope at hand, however. But now that theory ― inflation targeting ― is falling apart after almost 20 years of apparent success. And so the monetarists are back, in practice if not in policy statements.

What else do you think "quantitative easing" aims to achieve if not easier quantities of cash flowing from banks to business and households? And how can inflation targeting ― whether explicit as in the UK, or generally guessed to be the chief aim, as in the United States ― possibly survive this crisis given the failure of policy-makers to either hit target or reduce volatility?

It's not simply the impact of monetary policy on consumer inflation which has gone "off message" in 2009.

Extending their remit ― and now hoping also to control longer-term interest rates as well as overnight money rates in the "open" market ― central banks are signally failing to cap either the yield or volatility of long-term government bonds. The 10-year US Treasury bond, formerly the financial world's modern "Gold Standard" equivalent ― has never offered such wide-swinging returns.

Most disastrous for policy wonks pulling this lever and pushing that button, you have to go back to the Great Depression ― when central banks still nailed exchange rates and the volume of money to a tightly supplied quantum of gold bullion bars ― to find uncertainty about quite where the cost of living will stand running this great, this fast. The month-on-month rate of change in US consumer prices has been three times as vicious since December as the CPI's previous six-decade average. Here in the UK, consumer-price inflation has now overshot the official 2.0% target for 20 months running, even as the previous measure of living expenses ― the Retail Price Index ― has sunk below zero.

"We didn't abandon the inflation target," the Bank of England will no doubt declare. "It abandoned us..."

Thing is ― and as with any social experiment, such as the London Gold Pool's attempt to cap the price of gold in Dollars at $35 an ounce, finally abandoned in March 1968 ― trying to observe as well as influence the "out-turn" of inflation means neither task is done very well, if at all.

Promising to buy and sell gold in the "open" market at a fixed price lower than private traders would bid, the Gold Pool only invited fresh pressure on their fast-shrinking stockpiles. Defending that $35 price ― itself arbitrarily set by President Roosevelt at a series of jovial breakfast meetings three decades before ― showed the absurdity of any particular fixed value for gold in a world awash with money.

Now in 2009, and slashing rates towards zero to try and force savers out of cash and boost new mortgage debt, the Bank of England has itself caused those sub-zero readings on the Retail Price data ― the very opposite of what it set out to do. Because those numbers include mortgage-interest payments each month. Whereas the Bank's mandated target of 2.0% is pegged against the mortgage-less Consumer Price index. And on the logic of that measure alone, not least with oil prices about to start pushing higher on the year-on-year figure as the spike of July '08 fades from the series, interest rates should in fact now stand higher, rather than encouraging yet further hikes in the cost of living.

What to do? At this pace, we'll all join the Swiss in quietly setting targets for foreign exchange rates and ranges, hoping to side-step deflation at the expense of our neighbors' overseas exports. Already in March this year, the Bank of England's Spencer Dale cheered the fact that "the marked depreciation in Sterling should support demand, both at home and abroad, for domestically produced output." But that exchange-rate gain was swiftly undone as the Pound then raced back towards $1.65 to the Dollar, knocking 18% off the Gold Price in Sterling and widening the UK's trade deficit to £7.0bn in April from March's eight-year low of £6.5bn.

How to escape this policy nightmare? Besides yet more volatility, we guess that only one thing is certain. Central bankers scrabbling around for a new "Hey! This might work" policy to square the circle of full employment with low, stable inflation are guaranteed not to apply a fixed limit on the absolute volume of cash, as set by some implicit if not official Gold Standard.

Sure, if policy-makers, politicians and the rest of us would only abandon the hope of costless inflation, then yes ― a Gold Standard might well appeal. But the promise of above-average wealth for everyone makes yawning debt a necessity, and that makes a commodity-linked supply of money untenable. And anyone who tells you otherwise needs to review not only the one policy lesson taken away by every economic advisor who's studied the Great Depression, but also how unstable the "stability" of precious-metal standards proved in practice beforehand.

Digging deep in the archives three decades ago, Professor Roy W. Jastram of the University of California at Berkeley found that ― while relatively constant across broad sweeps of history ― holding gold even amid a Gold Standard didn't do much to smooth short-term volatility in prices.

As the table above shows, taken from Jastram's analysis of "the English experience" across 366 years, neither silver nor gold overcame shorter-term shocks to the cost of living, typically driven upwards by war. Indeed, the post-Gold Standard inflation of the 20th century proved the only exception. Precious metals rose ahead of the cost of living, gaining real value as the value of money diminished and commodities leapt. Whereas until the end of first the Silver, then bi-metallic and finally Gold Standard in the mid-1930s, it was deflation which boosted the real purchasing power of precious metals ― then, unlike now, hard cash you could take to the shops and exchange at the bank.

Quite what this means for central bankers now seeking the next number to chase in their monthly meetings, we neither know nor care. But for private investors seeking a little stability in their own savings and wealth, the one certainty remains vicious, violent changes in value, no matter what digit on what metric is chosen

 

I'd remarked at my surprise at both the volume and nature of the responses to James Howard Kunstler's "Too Stupid To Survive"; even the disagreement was relatively mild and positively civil…

But at last, an absolute howl of a protest has landed in my inbox:

This is my response to the latest spouting from James Howard Kunstler.  I am getting tired of his ad hominem attacks on people with opinions different from his.  "Stupidity", "doltish", "walnut brain", "techno-triumphalist mental illness", "psychotic techno-grandiosity" applied to people who have accomplished far more that Mr. Kunstler seems totally inappropriate.  Very few people share Mr. Kunstler's opinions, or we would all be doing things his way.  Does that tell him something?  As for his walkable cities, how does he propose to deal with the growing number of disabled people who cannot walk?  It is impossible for the entire population to be within reasonable walking distance from every service they need.

Sorry to have gotten your goat so thoroughly. But my best stock answer to this sort of response is thus:

We act as if the way we've arranged our built environment for the past hundred years is the only way…but for the millennia prior to 20th century, people simply built their cities, suburbs, hamlets and country manors with the expectation that they'd have to ― ya' know ― walk.

But along comes the Industrial Revolution. Mankind discovers bigger, better fire. He figures out how to harness the high energy density hydrocarbons. And all the old ways are summarily junked.

You wouldn't build your bathroom a mile from your bedroom…or your bedroom a mile from your living room and your kitchen a mile from everything else…Yet hydrocarbon man has gleefully eviscerated his urps and flung its innards far and wide: a housing-only pod here, another one there…a strip mall here, another one there.

And the remaining city itself? Knock the more beautiful buildings down so the highways have somewhere to dump suburban commuters. As population and wealth flee the city and once-pristine neighborhoods decay, knock those down, too, and put up some federally funded housing from the Brutalist school of architecture. Let the government corral its troublesome brown wards therein.

And so goes the saga of the Industrial Age, a time when mankind has said to itself "yea, verily, we are gods!" And who could argue? We are at least unto like Hermes if not Zeus.  With a gentle push of the pedal we can conquer time and distance without breaking a sweat.

At least we can for now. Who knows how this will end up? James Howard Kunstler is of one opinion with which I happen to agree (I tend to agree with the contributors I run ― fancy that!), but his vision isn't nearly as gloomy as those of others.

Of course, there are those who take exception to all this…like original Whiskey gangster Jim Amrhein who has a couple of coppers he'd like to toss in the pot concerning Mr. Kunstler:

Gary,

Well, it's nothing specific he said that's got me going...

It's the fact that his now-frequent, rarely parried contributions to W&G are keeping core points of his that have historically irked me more front-and-center in my consciousness.

Things like:

― His contempt for that particular segment of America (the NASCAR set) that historically and to a disproportionate degree raises the food and fights the wars, be they just or not...

― His unblinking willingness to sacrifice every American's freedom to live the way they want, where they want, in the service of dubious science and his own iron-fisted aesthetic...

― His continual glossing-over of the fact that only an all-encompassing government could bring about the militant uniformity of his car-less, oil-less, burb-less, individual-less Utopia...

― His apparent naiveté over the fact that pervasive government never acts in the true interests of the people they dominate, although they become pervasive on the promise to do so...

To be clear, I've got nothing against the man. I've met him several times, love to read him, think he's a great writer, admire him for his original thinking, and salute his success at well-timed and marketable novels.

However, his vision of an America made by (his) hand doesn't resemble anything like the "land of the free" that I'd hope we're all supposed to be endeavoring to bring to full fruition. It relies too heavily on scientific assumptions that aren't proven ― and even if they were, would be poorly served by the world of his own designing...

It's a world that beggars choice, invites (or forces) conformity to arbitrary instead of necessary standards, bastardizes liberty, marginalizes democracy, assassinates entrepreneurship that doesn't facilitate Central Planning's vision of the greater good, and is completely intolerant of the diversity of thought, aesthetic, or lifestyle that is America's very brand ― or used to be, anyway.

And like something out of Vonnegut or Huxley, it's a world in which Kunstler himself would have no problem dictating what's right, what's ugly, who can live where, what they eat, how they can obtain it, how they get from point A to point B, what's allowed to be said and written, and what's TRUE...

That's not an America I want to live in.
 
Yours Very Truly,

Jim Amrhein

Those of you who've been clamoring for the return of Jim Amrhein, well there you go. We eagerly await your responses.

One thing you have to understand, however, Shooters, is that we aren't counting on government diktat to lead us all into some ecologically sound utopian future. Whiskey tenet number five: things go wrong…often. Fate and thermodynamics will have their way with you, your species and your way of life.

So live! Drive! Be merry! For as long as you can afford it. Your humble editor promises not to sign into law any bills that will coerce you to live in line with his principles.

Here at the Whiskey Bar we frown heavily on coercion…but we do love lively conversation. So a hearty "Welcome back, Kotter" and thanks to Jim Amrhein! The rest of you, get crackin' on those letters.

And now…
Hi Gary,

Sometimes…I could just squeeze you!  Great stuff today, as always. However, I have an important question. As I am a single mom, self-employed and eking by, my investment dollars are extremely important to me and hard to replace. I am reading from sources I respect two decidedly different answers to the question � "Which way are we going?" Inflation or deflation? Do I bet on the dollar losing value and interest rates going up? Or is gold going to tumble hard? I feel absolutely stuck in cash and afraid to move out. I have side bets in both directions, but that can't go an forever, can it?

Aw shucks, thanks! We aim to entertain and inform. And we take your money as seriously as you do; you can't read Whiskey if you can't pay your internet bill or if you have died of starvation or exposure.

As Agora Financial founder and voice of The Daily Reckoning Bill Bonner says: "Deflation or inflation? Both!"

Collapsing credit makes dollars more valuable because there's less and less debt with which to bid up prices. But! That's the whole point of having a currency untethered by annoying tattletales like gold. You can just print up more of the stuff when you want to prop up prices and encourage "activity" in the economy.

Of course, that "activity" tends to end up being the increasing "velocity of money" which also looks a lot like hyperinflation. And that isn't so good.

Normally I'd follow this up with the caveat that we can know what will happen (like personal and irreversible death), but the when has ever proved to be the tricky part. Again, the inestimable Mr. Bonner posits that we'll see the usual bit of deflation until the Fed's attempt to combat it proves too successful.

I'd keep placing bets that the cash in my account could become worthless overnight. I think that eventually this currency will die just like all currencies do, but I also realize that it may well outlive me. Things do seem to be coming to a head, however.

We'll pick up this conversation next week.

In the meantime…we finally have a nice day here in Gotham-on-Patapsco.  I plan to wring some enjoyment out of it. Wherever this missive finds you, I hope you do the same.

Top Energy Stocks Better Than Oil

This energy source will be key to America's energy independence. It could also be the key to your financial independence.

Better than oil or solar and cleaner than nuclear…

Our resident geologist and energy expert Byron King has spent months coming up with a way for you to take advantage of this. So I hope you will read on to find out more…

On Friday March 20, the U.S. Environmental Protection Agency handed you the opportunity to make one of the first big fortunes of the 21st Century.

It made an announcement that will dramatically change the way energy is produced in this country. Early investors have an unprecedented opportunity to grab gains as high as 661%.

And you're among the first people to know about it.

Because, you see, the EPA didn't make a big deal about this. No one stepped before cameras and microphones. No one even issued a press release.

Only a few government officials even knew about this until the following Monday.

That's when the announcement showed up on the White House website — buried in a place almost no one would notice.

But make no mistake. Once President Obama adopts the EPA's declaration as official policy, you could grab a piece of a huge new fortune.

The White House could make its move on Thursday, April 2. Or any time before that.

So your window of opportunity here may not be very big. Jump on this now, or you run the chance of missing out for good.

Because right now, you're among a select few in the know. When President Obama goes public, everyone's going to know.

And here's the thing...

The coming White House announcement is just one of three mandates sure to turbo-charge this opportunity over the next 18 months.

I call this opportunity "Sonoma Grizzly Power."

And when you read the incredible story of its discovery, you'll know why.

How a 19th Century Bear Hunter's Brush With Death Made this 21st Century Opportunity Possible

Imagine for a moment...

You dangle from a crumbling cliff.

Your fingers dig into loose gravel.

1,500 feet below lies an abyss of steam.

Can you think of a worse fate?

That's exactly what William Bell Elliot faced on a sunny spring day in 1847.

Although he luckily pulled himself back up over the cliff's edge, he was certain he'd just glimpsed the gates of Hell.

Elliot, a legendary adventurer, set out bear hunting that day in the region we know today as California's Wine Country.

He was looking for a notorious grizzly known as "Old Slewfoot."

He climbed up a step embankment. He rounded the corner of a canyon. And suddenly, he found himself barely clinging to rocks above a 1,500-foot drop.

At the bottom of that drop was... nothing.

Nothing but roaring, steaming vapor.

One writer described it like this:

"The rocks burn under you; you're enveloped in fierce heat, strangled by puffs of diabolical vapor and stunned by the awful hissing, spitting, sputtering, roaring, threatening sounds."

Incredibly, Elliot never lost his senses... or his footing. He lived to tell about his brush with death for another 30 years.

But he never imagined this... in the 20th Century, a smart businessman would harness Elliot's discovery for electrical power. That's why I call it "Sonoma Grizzly Power"...

Nor did he imagine this... in the 21st Century, you could harness his discovery for profits of up to $63,359.

How "Sonoma Grizzly Power" Could Deliver You 661% Gains

According to a crack team of 18 MIT researchers, this single form of power could produce 2,000 times the amount of electricity America used in 2005.

And now a total of three government mandates could make it mainstream.

On Friday March 20, the Environmental Protection Agency made a dramatic announcement.

Only the EPA did it very quietly. Almost no one noticed. The White House will likely make it official within days. Perhaps April 2. Perhaps sooner.

What will it mean? The U.S. government could give early, visionary investors the chance to make historic profits. Here's how:

It practically ensures massive growth in electrical power generated by William Bell Elliot's discovery.

There's more...

A few weeks later, Congress could pass huge new taxes on power companies that don't adopt energy sources like "Sonoma Grizzly Power."

The expected White House announcement would all but force the hand of Congress to pass huge new taxes on electric utilities.

The only way they can avoid these taxes is to adopt green energy sources like "Sonoma Grizzly Power."

And there's more.

A California law is forcing power companies to produce 20% of their electricity from sources like "Sonoma Grizzly Power" by Dec. 31, 2010.

That's less than 24 months from now.

So there you have it. Three government mandates — two potentially forthcoming, and one already on the books — standing behind "Sonoma Grizzly Power."

And you could parlay these laws and regulations into gains of 661% or more.

If you act soon enough. Before April 2, 2009, that is...

I'll show you how in the next five minutes.

See, here's the really important thing. You can find "Sonoma Grizzly Power" in lots of places besides California wine country.

Most of them you'd never even guess existed. You see, the steaming vapor never reaches the earth's surface.

But it's still there. Ready to be tapped.

Massive "Sonoma Grizzly Power" Potential in the Western U.S.

Take a quick look at this map of America...

Put simply, the red areas on this map hold "hot spots" that broil close enough to the Earth's surface that you can drill into them to harness their heat to spin a turbine. The ideal potential lies in the states of California, Idaho, Oregon and Nevada.

That's why those MIT researchers say "Sonoma Grizzly Power" can generate 2,000 times the amount of electricity Americans used in 2005.

And those massive hot springs William Bell Elliot discovered in 1847? That one spot alone generates 750 megawatts of electricity today.

That's enough to power 750,000 homes, or a city the size of San Francisco.

How "Sonoma Grizzly Power" Could Soon Light all of San Francisco

Elliot called the place he found "The Geysers." And the name stuck.

Soon a developer built a resort in the area. It too was called The Geysers. Among its famous guests were Mark Twain, J.P. Morgan, and Theodore Roosevelt.

In the 1920s, a businessman named John Grant bought the resort and remodeled it. But he had bigger things on his mind. He was the visionary that first harnessed the sheer power of "Sonoma Grizzly Power."

You see, he figured the steam from the hot springs could be harnessed to produce electricity.

His workers drilled a hole into the earth, deep into an area where temperatures reach 400 degrees Fahrenheit.

Then they pumped water into the hole, boiling the water and producing steam. The steam powered a turbine to produce electricity.

Pretty simple: America's first "Sonoma Grizzly Power" plant was in operation.

Today, the resort is long gone. But the region around The Geysers produces huge amounts of California's non-carbon emitting electric power. More than solar and wind combined.

As I said, enough to power all of San Francisco.

And it works just like a coal or natural gas power plant.

Except those two types of plants use heat from burning fossil fuels to boil water. Then they use the steam to spin turbines.

But as you probably noted, "Sonoma Grizzly Power " pumps out hot steam WITHOUT burning any fossil fuels and without generating "greenhouse gases."

That stunning fact makes "Sonoma Grizzly Power" power the ultimate in non-carbon emitting energy.

And never more so than now.

Three catalysts are in motion right now that could bring "Sonoma Grizzly Power" into the mainstream by the end of 2010.

And one of them could hit as soon as April 2.

And I want to make absolutely sure that you get in on the first wave of government-forced "Sonoma Grizzly Power" profits...

Profit Catalyst #1: EPA Makes Major Declaration in Favor of "Sonoma Grizzly Power"

On Friday March 20, the Environmental Protection Agency made a big announcement.

The EPA declared carbon — "greenhouse gases" — is a threat to human or environmental health, paving the way for it to regulate carbon emissions the same way it regulates air pollution under the Clean Air Act of 1970.

This is HUGE.

It could give this one agency sweeping control over "transportation, manufacturing costs and how utilities generate power," according to the New York Times.

Now here's the thing. When the EPA made its announcement on Friday March 20, no one noticed. It was buried in an obscure spot on the White House website Monday March 23.

The details are still a secret. But the meaning is unmistakable. "It is going to set the stage for the first-ever national limits on global warming pollution," says Frank O'Donnell of the environmental group Clean Air Watch.

Now it's up to the White House to follow through with a formal declaration. It could very well come by Thursday, April 2.

Why April 2? It's the second anniversary of a historic Supreme Court ruling that ordered the EPA to decide whether carbon is a form of pollution.

Then again, the Obama administration could make its move any time before then now that the EPA's decision is public. That's why it's critical to move on this now.

Why is this so critical to the potential of "Sonoma Grizzly Power?"

Power plants, by far, churn out the largest chunk of greenhouse gases in the U.S. For instance, power generation emits 29.5% of the carbon dioxide released into the air.

Coal- and natural gas-fired power plants spew out the lion's share of that carbon dioxide. So you know that "Sonoma Grizzly Power" should get a large boost when the White House moves as early as April 2.

That means "Sonoma Grizzly Power" grants you government-mandated profit potential.

But that's just one of three government mandates — two that could be on their way, and one that's already on the books — lining up behind "Sonoma Grizzly Power."

The next one could come as soon as the White House makes its move.

Profit Catalyst #2: Congress Soon to Force "Sonoma Grizzly Power" Generation

According to the New York Times, the EPA's ruling "could accelerate the progress of energy and climate change legislation in Congress."

And it's already moving plenty fast.

In his first address to a joint session of Congress on Feb. 24, 2009, President Obama asked that the House and Senate "send me legislation that places a cap on carbon pollution and drives the production of more renewable energy in America."

He didn't even have to ask. Congressional leaders have already set the wheels in motion.

The idea goes by several names — "cap and trade" and "carbon tax" are the most common. You'll hear about them in the news after April 2.

The gist of it is this. Washington would set limits for nearly every American business on how much carbon it can pump into the atmosphere.

Government would put a "cap" on everyone's greenhouse gas emissions. Or else they'd have to pay Uncle Sam huge penalties.

Now here's the thing. You've already seen how power plants are the biggest source of greenhouse gases. That means electric utilities would be scrambling big-time to find power sources that don't generate greenhouse gases.

Sources like "Sonoma Grizzly Power."

Invest in the companies that provide "Sonoma Grizzly Power" to the utilities, and you stand to make government-mandated gains.

And there's one government mandate already on the books that stands behind "Sonoma Grizzly Power." I'll get to it in a few moments.

But at this point, you're probably asking: What's so great about "Sonoma Grizzly Power"? What makes it better than other non-carbon spewing energies like solar and wind?

Good questions...

How "Sonoma Grizzly Power" Power Churns Out Juice Nearly Four Times as Long as Solar

"Sonoma Grizzly Power" plants operate 24 hours a day. You can suck steam out of the ground around the clock. Obviously, solar cells don't capture any juice at night. Further, they capture less on cloudy days.

The percentage of time that a power source can make electricity is called "capacity factor." Solar power has a capacity factor of 25%. So over a one-day period, solar cells crank out juice for only six hours.

"Sonoma Grizzly Power's" capacity factor, on the other hand, ranges from 90% to as high as 98%. So a "Sonoma Grizzly Power " plant whips up electricity for at least 21.6 hours a day.

So on average, a "Sonoma Grizzly Power" plant can blast out electricity for almost four times as long as solar power.

Further, since demand for solar power has rocketed up so much over the past few years, a supply crunch has spanked the solar cell makers.

The solar cells' main raw material is silicon. And silicon refiners have scrambled to refine enough silicon to meet the rising solar cell demand. This scramble tightened silicon supply.

The semiconductor industry's large need for this same silicon chokes the supply problem even more. And since it takes many years to get a new silicon refinery online, you know the shortage won't solve itself overnight... Now, none of that means that solar investments have performed poorly in the recent years. Take a look at some solar stock performances:

First Solar for 492% MEMC for 79% Evergreen Solar for 66%

JA Solar for 219% Trina Solar for 224% SunPower for 236%

Yup, solar top stocks to buy had an impressive run earlier this decade.

Now, since we just proved that "Sonoma Grizzly Power" makes a better non-carbon emitting energy source, don't you think it has more investment potential than solar?

Kind of makes you wonder why no one talks about "Sonoma Grizzly Power."

Kind of makes you wonder which companies stand to make the most from "Sonoma Grizzly Power."

I'm ready to reveal five of them to you right now in a free report called, Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Grizzly Power."

I'll show you how to get your free copy of this limited-edition investment research report in a minute. For now, let's get back to showing how "Sonoma Grizzly Power" makes the best non-carbon emitting energy opportunity...

We showed how "Sonoma Grizzly Power" beats solar power. Now let's compare it with wind power.

How "Sonoma Grizzly Power" Can Help Heat Homes Three Times as Long as Wind Power

When you read that solar cells can produce power only 25% of the time, I bet you immediately thought about wind power. After all, the wind doesn't always blow.

Wind power's capacity factor clocks in a tad better than solar, with an average of 30–40%. But obviously, the 90–98% capacity of "Sonoma Grizzly Power" trumps that figure...

Furthermore, "NIMBYism" makes it tough for wind power to spread to certain areas. "NIMBY" sounds funny, but it simply means "not in my backyard." In some areas, large groups of people object to large construction and industrial programs that could change the environment.

This "NIMBYism" happens frequently with wind power. In populated areas with high average incomes, few people care to watch a sunset sliced up by hundreds of towering windmills. Not from the deck of a million-dollar home!

"Sonoma Grizzly Power" plants, on the other hand, look tiny. They're sometimes as small as houses. So few, if any, "NIMBY" complaints get lodged against "Sonoma Grizzly Power" generation.

So now that we've shown how "Sonoma Grizzly Power" outperforms wind power, let's take a look at how some wind stocks did in recent years:

Vesta Wind Systems for 107% Gamesa Corp. for 79% American Semiconductor for 168%

NaiKun Wind Energy for 404% Western Wind Energy for 132% Kaydon Corp. for 31%

Those gains look pretty good, don't they?

So if wind has done that well and "Sonoma Grizzly Power" performs better than wind power, shouldn't "Sonoma Grizzly Power" attract your investment attention?

Especially now, when the U.S. government is trying to virtually FORCE legislation that could give you a chance to make $63,359...

Thought so... and you'll soon learn how to obtain your FREE report about the best pure plays on "Sonoma Grizzly Power"...

But for now, you need to know about one government mandate — already on the books — that makes "Sonoma Grizzly Power" a one-of-a-kind opportunity.

Profit Catalyst #3: How the California Government Will Force Massive Growth in Energy Sources Like "Sonoma Grizzly Power" Over the Next 1½ Years

California recently passed Senate Bill 107.

This bill says that 20% of electricity sold in the state must come from non-carbon emitting sources by Dec. 30, 2010. And Gov. Schwarzenegger hurried to place a 33% target by 2020.

Let's put those numbers into perspective...

First, you should know that California has the world's sixth largest economy. That's big. Bigger than the entire countries of Italy and China!

And according to a 2008 estimate, nearly 37,000,000 people live in California. Further, the state adds 500,000 more folks every year.

So that means that by December 2010, at least 7.4 million Californians are slated to get all of their electricity from non-carbon emitting sources like "Sonoma Grizzly Power."

And when you add the huge amount of juice that runs the businesses such as Google and the Silicon Valley crowd, you have a massive and urgent need for increased renewable energy capacity.

That gives California barely a year and a half to meet a deadline that drastically increases the amount of renewable electricity sold in the state. That will benefit the producers of non-carbon emitting energy like "Sonoma Grizzly Power."

So renewable energy must grow a lot. And fast.

But just how much must it grow?

Well, right now, the state generates 10.2% of its electricity from non-carbon emitting sources. So that means the amount of renewable energy must DOUBLE in just under a year and a half.

Quite an ambitious goal. Don't you think that could pay off big for the investor willing to find the best California renewable energy plays?

And that brings us to the most important question I suspect you're wondering: "So how much money can I make?"

Well, if you act quickly and move on these opportunities now — before the White House and Congress make their moves as early as April 2 — they could make you $63,359.

Act aggressively, and it could mean your take is as high as $253,434.

How "Sonoma Grizzly Power" Could Be Worth $253,434 to You

How can I say that you could grab $253,434 with such confidence?

Well, consider this: MSNBC reports that "Sonoma Grizzly Power" production could soon equal that of all 104 nuclear power plants in the U.S.

Decades ago, when nuclear plants were first coming online, energy investors rushed in. And nuclear companies made massive profits for shareholders:

Entergy Corp. of New Orleans ran up 261% between 2000 and 2006

Dominion raced up 110% during the same period

Cameco Corp. (a uranium miner) returned 1,551%

Say you bought just 500 shares of each of these companies when nuclear power was coming into widespread use. You'd make $63,359 in pure profits.

If you'd taken a more substantial stake — 2,000 shares — you'd be looking at $253,434.

And that's the sort of potential that lies in "Sonoma Grizzly Power" right now.

So let's quickly sum up the case for "Sonoma Grizzly Power."

Why You Should Invest in "Sonoma Grizzly Power" Right Now:

The EPA is expected to declare it has the power to regulate greenhouse gases... perhaps as early as April 2... which would place "Sonoma Grizzly Power" ahead of coal, gas, and oil-generated electricity

Congress could then follow up with cap-and-trade legislation that would tax power companies depending on the amount of greenhouse gases they produce

The California Senate will force non-carbon emitting energy production to double in just under a year and a half

"Sonoma Grizzly Power" beats all other known non-carbon emitting energies, including solar, wind and hydro

The profit potential of "Sonoma Grizzly Power" is comparable to that of nuclear power earlier this decade — when 2,000 shares of just three companies could have made $253,434

That explains my enthusiasm for "Sonoma Grizzly Power." And it explains my eagerness to reveal five pure plays on "Sonoma Grizzly Power."

Every one of these companies can be yours for under a dollar a share.

You can load up on 1,000 shares of each for just $2,760.

But this opportunity won't last long. See, you're reading about "Sonoma Grizzly Power" right now. But if the White House and Congress act as early as April 2, everyone will know about it.

And within days everyone will know which companies stand to profit the most. After that, a good chunk of the government-forced gains may be off the table...

That's why I want to get this information in your hands NOW. I want you to see the FREE special report called Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Grizzly Power".

But please allow me to introduce myself before I get ahead of everything...

Why This Old Rockhound Got Obsessed With "Sonoma Grizzly Power"

Hello, I'm Byron King.

You may know me from the investment research newsletter Outstanding Investments, which I helm as managing editor.

Outstanding Investments focuses solely on resource-related top stocks for 2010. We're talking gold, oil, cement, timber, alternative energy, uranium, coal and water. You know, all the "stuff" we need to live and build things.

Or you may have read my resource- and history-related writings in the internationally renowned e-letter Whiskey & Gunpowder.

You see, I focus most of my time on the resource, energy and commodity sphere of investing. And you've obviously seen my present obsession with the innovative resource of "Sonoma Grizzly Power."

Why does the commodity segment of the market demand my time?

Enter the "old rockhound" part... I've studied geology for almost 40 years now. Back in the '70s, I graduated from Harvard with a geology degree.

I immediately went to go work in the exploration and production division of an oil major. The geologist's main task: to tell the oilman where to drill. Quite important, yes?

I've also held membership in the American Association of Petroleum Geologists for over 30 years. So after I stopped working as an active geologist, I turned all of my attention to discovering investment opportunities in oil and the resource sector in general.

That's why I love to research and write about commodity and resource top stocks to buy in Outstanding Investments.

I also have quite some pride in the fact that Outstanding Investments was judged the best-performing newsletter in the world over a five-year period in 2005, 2006, and 2007. That's according to the independent watchdog Hulbert Financial Digest.

Don't take my word for it, though. Let's look at some specifics:

How about some samplings of past triple-digit Outstanding Investments recommendations:

332% on Glamis Gold 668% on Metallica Resources 162% on Intrepid Minerals 137% in KeyWest Energy 263% on Coeur D'Alene 228% on Niko Resources 151% on Tocqueville Gold

Of course, you should never frown on a nice double-digit gainer.

Outstanding Investments has pumped out a healthy helping of these kinds of gains, as well:

96% on EOG Resources 75% on American Water 84% on Corner Bay 57% on Waste Management 88% on Northgate Exploration 55% on Atacama Minerals 80% on Anadarko Petroleum

The above triple- and double-digit closed plays could've made my Outstanding Investments readers rather wealthy.

But just to complete the picture, let's take a quick look at some of the plays still open in the Outstanding Investments portfolio*:

100% on a gold miner 135% on an oil and gas producer 147% on an oil refiner 237% on a Canadian oil sands firm 291% on a very well-managed gold fund

* Please note: In fairness to existing Outstanding Investments subscribers, I can't reveal the names of the companies still open in the portfolio. All gains as of Feb. 26, 2009.

Here are a few comments from satisfied readers:

Am Very Pleased With Your Newsletter
"Just wanted to write a quick note. I am very pleased with the Outstanding Investments newsletter. I appreciate the personal touch and the weekly commentaries, as well. And boy, do you guys know how to pick 'em. It's nice to find a buy-and-hold newsletter that delivers."

— Kevin S.

Thanks for Making My Family Money
"I just thought you would like to know that one guy out here is watching, impressed, happy, and has a few more shekels to share with his family."

— Randy Gale

Up Over 8% in Less Than a Day
"A tip of my hat to you. I have subscribed for some time now, but didn't act until yesterday, when I followed your recommendation and bought 1,000 shares. I'm now up more than 8% in less than 24 hours. It seemed like a gutsy call."

— Bruce

Profits of 560% and 652%... I'm up $45,000!
"Our financial year runs July to June, and so far, I am up some $45,000.

"On Monday, I sold for a profit of 560%. Today was my birthday, and you gave me the greatest birthday present I have ever had (financially) — a profit of 652%...

"I am absolutely rapt, as I have never traded commodities until now."

— G. Cockburn

52% in 8 Months
"My stock portfolio has increased 52% in eight months as a result of the insight of Outstanding Investments. I plan to be a subscriber for years to come. Thanks."

— Fred Handschumacher

I Made up the Cost of the Subscription Within a Week!
"I made the cost of the subscription on my first buy, within a week or so. Your newsletter is a great deal!"

— A. Depalmer

Subscribing Was One of the Best Investment Decisions I've Made
"Thanks for all of the good advice. Subscribing to Outstanding Investments was one of the best investment decisions I've ever made."

— G. Wade George

So you wonder why I don't share my tiny "Sonoma Grizzly Power" companies with Outstanding Investments members? Simple answer: because I can't.

You see, since Outstanding Investments has the best five-year record in the world, it has attracted a large number of eager members. Over 48,000, to be exact. And at under $1 per share, these "Sonoma Grizzly Power" plays are just too small for that amount of interest.

There's no way I can possibly send out those "Sonoma Grizzly Power" recommendations to the high number of potential investors who read Outstanding Investments.

You see, these companies are so small that the hot stocks to buy are microcaps. They cost less than a $1 a share. Some less than 20 cents. And further, a relatively small number of shares trade each day. This makes these top stocks fairly illiquid.

If we told 48,000 people about a stock that small — frankly — all hell would bust loose.

The shares' trading volume could get slammed up by all of the buying interest. This could artificially affect the stock's price. We can't have that...

But a problem comes up with my silence about this awesome "Sonoma Grizzly Power" opportunity. These particular top stocks 2010 have such strong profit potential that I can't possibly keep silent about it.

So I thought hard until I came up with a solution. I had to create a new research service that focuses only on these tiny, unknown microcap resource companies.

Companies so small that I can't recommend them to more than a small handful of skillful opportunists. Companies that promise outsized, underground gains.

Introducing Energy & Scarcity Investor

I call my small and midcap resource stock research service Energy & Scarcity Investor.

Energy & Scarcity Investor follows the premise of my life's passion and present work in Outstanding Investments: finding great resource stocks. Resource stocks that promise incredible gains in a decades-long commodity bull market...

The basic tenet of the new service is to show you gains from the most necessary — and scarce — resources through the realm of speculative and tiny commodity and energy stocks.

Stocks exactly like the under-$1 "Sonoma Grizzly Power" makers that I'll reveal to you in three minutes.

Whether those energy stocks trade on the Amex, the Bulletin Boards, the Pink Sheets or even a foreign exchange like the TSX Venture... Energy & Scarcity Investor will scour any exchange, anywhere, to show you the best tiny, unheard-of commodity stocks.

Now, we must have a word about risk and sophistication.

Why Energy & Scarcity Investor  Isn't Right for Beginners

Clearly, these microcap plays are more speculative than getting involved with, say, an established blue chip major like Exxon.

For this reason, you need an increased tolerance for risk to use the research in Energy & Scarcity Investor.

As you know, the larger the chance for gain, the larger your risk. That simple fact will never vanish.

Now that doesn't mean we should shy away from the explosive profit potential that microcap resource plays like "Sonoma Grizzly Power" offers. It just means that we have to treat these companies with more diligence. We must approach the opportunities with more sophistication. With more courage against risk.

These important qualities make Energy & Scarcity Investor a smaller, more elite service.

Beginning investors shouldn't subscribe.

But if this is something you think you're ready for, just take a look at some top stocks to buy in the sectors that Energy & Scarcity Investor covers.

Explosive Gains From Tiny Resource and Energy Stocks

For proof of the concept behind my new service, let me show you some past impressive gains from micro- and small-cap resource stocks just like the ones that Energy & Scarcity Investor will focus on:

700% on Almaden Resources 450% on Antares Minerals 1,258% on Bear Creek Mining 4,500% on Brett Resources 1,236% on Dynasty Metals 2,860% on Denison Mines 428% on Cirrus Energy 1,376% on Enexco

214% on Pan Orient Energy 211% on Ur-Energy 1,062% on Virginia Mines 958% on Seabridge Gold 1,076% on Minefinders 732% on Pan American Silver 208% on Compass Minerals 2,568% on Silvercorp Metals.

Energy & Scarcity Investor aims for those impressive quadruple- and high triple-digit gainers.

In fact, I have a good feeling that the "Sonoma Grizzly Power" plays that got me so excited have potential like that. And I reveal all of them in your free report called "Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Steam Power."

Every one of them has explosive triple-digit potential. The sort of potential that could be had with nuclear power in days gone by. The sort of potential you can start to unlock even before the feds move to crack down on carbon dioxide as early as April 2.

Sonoma Grizzly Power Play #1: Take advantage of this company's 20-year exclusive deal. This company already produces Sonoma Grizzly Power at a site in Idaho. One day it could power 110,000 electric customers. The U.S. Department of Energy has awarded this company a $9 million grant to experiment with cutting-edge technology at this site to exploit "Sonoma Grizzly Power." And the firm is working to bring a second site online, with what it calls "the potential for prolific production."

Sonoma Grizzly Power Play #2: Another 20-year exclusive deal. This firm in Nevada has an exclusive 20-year agreement to power 24,000 homes in Nevada. Its site goes on line by the end of 2009. And the U.S. Department of Energy has awarded this company a $1.25 million grant to begin extracting energy from a second site.

Sonoma Grizzly Power Play #3: 70,000 acres of "hot spots" waiting to be tapped. This company owns rights to 15 locations in California and Nevada totaling 70,000 acres. Five of its sites are already in development. And now it's on Wall Street's radar. Standard and Poor's just assigned an analyst to follow the company.

Sonoma Grizzly Power Play #4: Access to 277,000 power customers in Latin America. This tiny dynamo expects just one "hot spot" south of the border to generate enough power for 277,000 people. And like the first two companies I mentioned, it recently signed an exclusive 20-year contract.

Sonoma Grizzly Power Play #5: The best of the bunch. I'm saving the best for last here. This company is an industry leader, with two major "hot spot" projects in the works. One is about 75 miles north of San Francisco, and it's the largest active energy-producing field in the world. The other is in British Columbia, and estimates show it could power 80,000 homes in Western Canada.

So that sums up the five total "Sonoma Grizzly Power" pure plays you'll get in your free copy of Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Grizzly Power."

But I have to underscore the need to move quickly on this: The White House could give its blessing to "Sonoma Grizzly Power" as early as April 2.

Now... if you act before April 2, I want to send you two more special reports. They're also free. And they spell out two more great opportunities in non-carbon emitting energy that you won't read about anywhere in the mainstream.

How a Century-Old Company. . . Using Century-Old Technology. . . Will Finally Make Solar and Wind Profitable

I told you earlier about one of the big problems with solar and wind power. The sun doesn't shine 24/7. The wind doesn't blow 24/7.

That means you need a way to generate power at night, and when the wind is calm.

Now here's the thing. Often when the sun shines, solar panels might draw in more power than customers need at the other end of the transmission line.

Same thing with wind. The wind can blow so hard, it generates more power than customers use.

So it's pretty obvious. There needs to be some sort of way to store that excess power.

So when the sun doesn't shine and the wind doesn't blow, there's still power that people can use.

That's not just a matter of common sense. It's also a matter of economics.

Without some way to store that excess power for later use... it might never be cost-effective to generate solar and wind power on a large scale.

What's the best way to store that power?

It happens to be technology that's been around for over a century.

It's good old-fashioned batteries.

I'm talking lead-acid batteries, bigger (much bigger) versions of what's in your car.

Mega-Batteries: Built for Old-Fashioned Submarines, Ideal for Cutting-Edge Solar and Wind Power

These mega-batteries will be the key to storing up excess solar and wind power, then sending it down the line when people need it most.

And one company will lead the field. It's been an industry leader in lead-acid batteries for as long as it's been around.

This company has built batteries for submarines for over 100 years. They're so reliable, they supply power for every nuclear sub in the U.S. Navy.

And the firm's scientists are working their tails off to make even better batteries. They've already developed a method to ensure no leakage... even if the battery case is punctured. And now they're also working on methods to make the batteries last longer.

Bottom line: I can't think of a better route to riches in solar and wind. Without this company's technology, large-scale wind and solar power just won't happen.

Now you've already seen how the government is going to push electric utilities into non-carbon emitting energy sources, including solar and wind... So just like the "Sonoma Grizzly Power" companies, this company can't help but benefit.

And so can you. I showed you earlier how profitable some solar stocks have been. In fact, in 2007, an index of solar stocks jumped 162%. Once this company makes large-scale solar power economical, gains of 162% in its shares could become a yearly phenomenon. A $5,000 investment becomes $13,100.

I can't wait to tell you about it in another FREE special report. This one's called Mega Batteries: The Company That Could Double Your Money By Making Solar and Wind Profitable.

You can get it along with the other FREE report, Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Grizzly Power."

And I'm not done telling you about cutting-edge ways to make money in alternative energy. Check out this method of "clean" power generation.

"Pocket Power Plants" - Clean, Green, and Efficient

Imagine taking a whole electric power plant and shrinking it to the size of a refrigerator.

No, it couldn't power an entire city. But what if I told you a power plant that size could power 250 homes? Or a big-city hotel?

And what if I told you thousands of power plants just like these are already in use?

This is one of the greatest open secrets in energy these days. I call them Pocket Power Plants.

Usually they rely on clean-burning natural gas. The gas feeds these Pocket Power Plants to generate electricity independent of the grid.

Pocket Power Plants already supply the electricity for the Ronald Reagan Presidential Library in California. That's a complex so huge, it houses the jet that served as Reagan's Air Force One.

Pocket Power Plants supply the electricity for the Manhattan Marriott hotel.

Running a Pocket Power Plant is often cheaper than buying electricity from the power company. And it's so efficient, the heat it throws off can be recycled to run-air conditioning!

Now, there's a fair amount of competition to make Pocket Power Plants. So which company is your best bet?

I know of an American firm that has a leg up. It invested years ago in state-of-the-art robotics and software to make its Pocket Power Plants.

And that investment is starting to pay off big. Its order backlog has grown 458% in just a year. That's right, demand has grown by five and a half times in just a year.

So everyone from oil drillers to owners of big buildings like hospitals and office towers are beating down the doors of this company to get its products. And with its high-tech production line, it has the means to meet that demand.

Now I can't guarantee that 458% growth in orders will translate to 458% gains if you hold the shares for a year. But even if the gains were a quarter of that figure, you'd still more than double your money. A $5,000 investment becomes $10,725.

I can't wait to tell you about this company in another special report. This one's called Outsize Profits From Pocket Power Plants. This too is yours FREE with a membership in Energy and Scarcity Investor.

Now let's cover the additional benefits you'll receive when you join Energy & Scarcity Investor...

Here's What You Get With Your Membership in Energy and Scarcity Investor

You can become a member of Energy and Scarcity Investor today and start profiting as soon as the feds take action on carbon emissions, perhaps as early as April 2.

Here's what you get with your membership.

Profit From the Gov't-Forced Boom in Renewable Energy With "Sonoma Grizzly Power." This FREE special memo on microcap "Sonoma Grizzly Power" companies contains five pure plays for you to take advantage of. I will e-mail you this report if you're among the next 2,000 people who subscribe. Value: $795

Mega Batteries: The Company That Could Double Your Money By Making Solar and Wind Profitable. This FREE special report reveals the one company that can make solar and wind power cost-effective. Value: $160

Outsize Profits From Pocket Power Plants. This FREE special report tells you all about the key to cheap and efficient power generation for buildings... and even fuel for trucks and buses. Value: $160

Monthly issues of Energy & Scarcity Investor. Every month, I'll identify yet another company set to transform scarce natural resources into triple-digit gains. Value: $1,495 per year.

Weekly Energy & Scarcity Investor email updates. Every Friday afternoon, I'll update the state of your positions, along with any news that affects the outlook for natural resource stocks. Value: $495 per year.

Flash Buy Alerts via email. From time to time, a buying opportunity will emerge that can't wait for the monthly issue. So I'll issue a Flash Buy Alert while the opportunity is hottest. Value: $295 per year.

Members-only access to the Energy & Scarcity Investor website. Here you can review archived issues and email updates using a password you'll get as soon as you receive access to your FREE special reports.

Total value of one year of Energy & Scarcity Investor = $3,400

Plus you get a free subscription, if you don't already have one, to Whiskey & Gunpowder — the daily e-letter for resource profiteers and freedom lovers like you.

And you get the Agora Financial Executive Series. The morning's Rude Awakening and the afternoon's 5 Min. Forecast give you access to the entire universe of Agora Financial's research.

$3,400 looks pretty cheap, compared with what you'd pay for other high-end research services.

And you can bet you'd have the opportunity to recoup that $3,400 in no time if we showed you a triple- or quadruple-digit winner... And, as you've seen, the government's actions could FORCE you to make as much as $63,359 from "Sonoma Grizzly Power" alone!

But don't worry: You won't pay nearly that much to accept your membership.

The price for one year is just $1,495. That's a better-than 50% discount off the one-year value of $3,400.
Price SLASHED until April 2. Click button below to see your final discounted membership fee.

But there's one last catch:

Hold on — you could actually get two months of Energy & Scarcity Investor completely risk free...

Why You Can Try out My "Sonoma Grizzly Power" Power Research for $0

That's right. I want to give you the chance to pay nothing to try out my Energy & Scarcity Investor.

$0!

How it works: You receive your "Sonoma Grizzly Power" report, plus the two additional reports I mentioned. You decide if you want to invest in any or all of those stocks. Soon, your monthly issues arrive. You get your weekly updates and exclusive password access to the member-only Web site...

You decide which, if any, recommendations you want to act on. Whichever you want.

My guarantee: If, after two months, you're not satisfied with the opportunities my Energy & Scarcity Investor picks have shown you, you can call me and demand a full refund.

You heard that right. If you're not satisfied with your membership, you pay nothing for it.

Even in the last hour of the 60th day. No questions asked. And you keep every single thing I've ever sent you.

I think that's the simplest guarantee in all independent investment research.

Couldn't be fairer than that, could it?

Like I said, the first move up in "Sonoma Grizzly Power" stocks could be forced by the U.S. government as early as April 2, 2009.